FDA approves first gene therapy targeting rare form of inherited blindness
BREAKING: FDA approves a first-of-its-kind gene therapy to treat a rare, inherited form of childhood blindness.
A first-of-its-kind gene therapy received approval from the Food and Drug Administration on Tuesday to treat a rare, inherited form of childhood blindness.
The FDA marketing clearance of Spark Therapeutics’s is historic for scientific and financial reasons. Luxturna is the first gene therapy approved in the U.S. that targets a disease caused by mutations in a specific gene.
